Estimaciones de analistas de Wall Street para CervoMed Inc. (CRVO): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 7 |
| Mantener | 0 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 7 |
| Calificación media (1-5) | 1.00 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.61 | ||
| 2026-08-10 | $-0.64 | $-0.80 | +19.7% |
| 2026-05-18 | $-0.86 | $-0.90 | +4.4% |
| 2026-03-13 | $-0.88 | $-0.79 | -11.4% |
| 2025-11-07 | $-0.84 | $-0.68 | -23.5% |
| 2025-08-08 | $-0.70 | $-0.61 | -13.9% |
| 2025-05-12 | $-0.56 | $-0.60 | +6.7% |
| 2025-03-17 | $-0.80 | $-0.67 | -19.4% |
Ratios de valoración
| Precio / Valor contable | 1.09 |
| EV / EBITDA | -0.03 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $25342 | $67981 | $110371 | $97915 | $103168 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | -$25342 | -$67981 | -$110000 | -$97915 | -$103168 | 0 | 0 | 0 | 0 | 0 |
| I+D | $6.3M | $5.1M | $5.8M | $6.6M | $9.4M | $8.5M | $1.3M | $8.4M | $18.8M | $21.8M |
| Generales y Administrativos | $8.6M | $6.2M | $6.2M | $4.8M | $6.4M | $7.4M | $2.1M | $6.5M | $9.2M | $10.5M |
| Gastos Operativos | $14.8M | $11.3M | $11.9M | $11.5M | $15.9M | $24.7M | $3.5M | $7.8M | $18.2M | $28.3M |
| Beneficio Operativo | -$14.9M | -$11.3M | -$12.0M | -$11.6M | -$16.0M | -$24.7M | -$3.5M | -$7.8M | -$18.2M | -$28.3M |
| EBITDA | -$18.3M | $566010 | -$18.7M | -$11.4M | -$15.8M | -$15.9M | -$5.8M | -$2.2M | -$16.3M | -$27.0M |
| Gastos por Intereses | $29686 | $2.9M | 0 | 0 | 0 | 0 | $587 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$18.4M | -$2.4M | -$18.8M | -$11.5M | -$15.9M | -$24.5M | -$5.8M | -$2.2M | -$16.3M | -$27.0M |
| Impuestos | -$365000 | -$1.1M | -$437000 | $332885 | -$1.7M | -$443893 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$18.0M | -$1.4M | -$18.4M | -$11.8M | -$14.2M | -$24.1M | -$5.8M | -$2.2M | -$16.3M | -$27.0M |
| BPA | $-1982.96 | $-123.33 | $-424.93 | $-131.95 | $-22.50 | $-18.51 | $-11.20 | $-0.82 | $-2.02 | $-2.98 |
| BPA Diluido | $-1982.96 | $-120.35 | $-424.93 | $-131.95 | $-22.50 | $-18.51 | $-11.20 | $-0.82 | $-2.02 | $-2.98 |
| Acciones en Circulación (Diluidas) | $9095 | $11338 | $43230 | $89420 | $717759 | $1.3M | $518139 | $2.7M | $8.1M | $9.0M |
Precio
| Precio | $2.44 |
| Capitalización | $23M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ACET · ADAG · FBIO · GANX · LITS · NRXP · NTRB
Explorar sector: Healthcare · Biotechnology
Más secciones de CRVO: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones